Investment Rating - The report assigns an investment rating of "Buy" for the company, indicating a positive outlook based on its stable generics business and growth potential in small nucleic acid drugs [5]. Core Insights - The company has a solid foundation in generics, with a stable growth phase, and is strategically positioning itself in the small nucleic acid innovation space, which is expected to drive long-term growth [7][10]. - The generics business is projected to maintain steady cash flow, while the innovative drug segment is anticipated to create a second growth curve, enhancing the company's overall valuation [8][10]. Summary by Relevant Sections Market Performance - The closing price of the company's stock is 28.82 yuan, with a market capitalization of 13,833.60 million yuan [3]. Financial Forecast and Valuation - Revenue projections for 2023 to 2027 are as follows: 3,340 million yuan (2023), 3,446 million yuan (2024), 3,472 million yuan (2025E), 3,852 million yuan (2026E), and 4,266 million yuan (2027E) [6]. - The expected growth rates for revenue are 3.07% (2023), 3.17% (2024), 0.75% (2025), 10.95% (2026), and 10.74% (2027) [6]. - The projected net profit for the same years is 489 million yuan (2023), 489 million yuan (2024), 465 million yuan (2025), 481 million yuan (2026), and 520 million yuan (2027) [6]. - The company’s price-to-earnings (P/E) ratios are estimated at 28.30 (2023), 28.31 (2024), 29.78 (2025), 28.76 (2026), and 26.61 (2027) [6]. Business Overview - The company, formerly known as Wansheng Pharmaceutical, has been in the generics business for over 20 years and has recently expanded into innovative drugs, particularly small nucleic acids [7]. - As of the first half of 2025, the company holds 209 domestic drug registration approvals, with a revenue contribution of 32.09 billion yuan from drug formulations, accounting for 93% of total revenue [7][20]. - The company’s core therapeutic areas include cardiovascular, diabetes, digestive, skin diseases, and chronic kidney disease, which collectively contribute 77% of its revenue [20]. Growth Drivers - The generics business is entering a stable growth phase, with a compound annual growth rate (CAGR) of 7.75% from 2019 to 2024 [10]. - The company is actively investing in small nucleic acid drugs, with R&D expenses increasing from 180 million yuan in 2021 to 417 million yuan in 2024 [10][49]. - The N-ER platform for nucleic acid drug delivery has been established, supporting multiple projects in clinical development [50]. Competitive Position - The company has successfully navigated the challenges posed by national drug procurement policies, with a significant portion of its core products already included in procurement programs [32][43]. - The upcoming unified procurement for previously selected products is expected to stabilize cash flow and enhance the company's competitive position in the generics market [42][43].